| Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants | Frontiers in pharmacology |  | | 2026 | 21 | 37 |
|
| Therapeutic drug monitoring and point-of-care technologies: Opportunities and current challenges | Therapeutic drug monitoring | | | 2026 | 7 | 147 |
|
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | | | 2025 | 81 | 232 |
|
| Population pharmacokinetics in oncology and its clinical applications | Pharmaceutics | | | 2024 | 61 | 118 |
|
| Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in Switzerland | The Lancet regional health. Europe | | | 2024 | 17 | 131 |
|
| Isavuconazole for the Treatment of Fungal Infections : A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS) | Open forum infectious diseases | | | 2024 | 91 | 251 |
|
| Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV | Frontiers in pharmacology | | | 2024 | 17 | 117 |
|
| Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study | Cancers | | | 2024 | 82 | 377 |
|
| Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV | Clinical pharmacology and therapeutics | | | 2024 | 101 | 372 |
|
| Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study | Cancers | | | 2023 | 184 | 112 |
|
| Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective | Pharmaceutics | | | 2023 | 83 | 220 |
|
| From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure | Pharmaceutics | | | 2023 | 138 | 187 |
|
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | | | 2023 | 144 | 532 |
|
| Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland | Pharmaceutics | | | 2022 | 79 | 217 |
|
| Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation | The journal of antimicrobial chemotherapy |  | | 2022 | 111 | 0 |
|
| Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation | Clinical pharmacology and therapeutics | | | 2022 | 175 | 353 |
|
| Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer | Pharmaceutics | | | 2022 | 139 | 248 |
|
| Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial | British journal of clinical pharmacology | | | 2021 | 231 | 0 |
|
| Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study | CPT: pharmacometrics & systems pharmacology | | | 2021 | 89 | 142 |
|
| The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib | Frontiers in Pharmacology | | | 2020 | 370 | 384 |
|
| A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk | British Journal of Clinical Pharmacology | | | 2020 | 452 | 2 |
|
| Population pharmacokinetics of erlotinib in patients with non-small cell lung cancer: Its application for individualized dosing regimens in older patients | Clinical Therapeutics | | | 2020 | 387 | 1 |
|
| Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review | Therapeutic Drug Monitoring | | | 2020 | 268 | 1 |
|
| Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections | The journal of antimicrobial chemotherapy | | | 2018 | 71 | 341 |
|
| Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance | British journal of clinical pharmacology | | | 2014 | 609 | 0 |
|
| Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals | Pharmacogenetics and genomics | | | 2013 | 676 | 0 |
|
